Literature DB >> 16574486

Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis.

Stephen G Waxman1.   

Abstract

It is now clear that effective treatments for nervous system disorders such as multiple sclerosis (MS) represent achievable objectives. Molecular mechanisms of axonal degeneration - a major pathological substrate for disability in MS - have been identified, pointing to the possibility of neuroprotection. Although previous studies were mainly carried out in laboratory models, recent analyses of human MS tissue have identified molecular targets that are related to mitochondrial function and specific isoforms of ion channels as contributors to axonal degeneration in MS. Taken together, the observations in model systems and in human tissue converge on the identification of a group of molecules that are related to ion fluxes and energetics as significant actors in the axonal-injury cascade, and suggest a set of molecular targets that might be useful in the development of new therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574486     DOI: 10.1016/j.molmed.2006.03.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  26 in total

1.  The properties of axons differ according to their function.

Authors:  David Burke
Journal:  J Physiol       Date:  2006-10-19       Impact factor: 5.182

2.  Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy.

Authors:  Helmar C Lehmann; Weiran Chen; Jasenka Borzan; Joseph L Mankowski; Ahmet Höke
Journal:  Ann Neurol       Date:  2010-11-08       Impact factor: 10.422

3.  Role of nuclear factor-κB in oxidative stress associated with rabies virus infection of adult rat dorsal root ganglion neurons.

Authors:  Wafa Kammouni; Leena Hasan; Ali Saleh; Heidi Wood; Paul Fernyhough; Alan C Jackson
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

Review 4.  Sodium MRI of multiple sclerosis.

Authors:  Maria Petracca; Lazar Fleysher; Niels Oesingmann; Matilde Inglese
Journal:  NMR Biomed       Date:  2015-04-06       Impact factor: 4.044

Review 5.  Neurodegeneration in Progressive Multiple Sclerosis.

Authors:  Graham Campbell; Don Mahad
Journal:  Cold Spring Harb Perspect Med       Date:  2018-10-01       Impact factor: 6.915

6.  Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression.

Authors:  William T Regenold; Pornima Phatak; Michael J Makley; Roger D Stone; Mitchel A Kling
Journal:  J Neurol Sci       Date:  2008-09-09       Impact factor: 3.181

Review 7.  Therapeutic potential of fluoxetine in neurological disorders.

Authors:  Jop P Mostert; Marcus W Koch; Marco Heerings; Dorothea J Heersema; Jacques De Keyser
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

8.  Maintaining energy homeostasis is an essential component of Wld(S)-mediated axon protection.

Authors:  Hua Shen; Krzysztof L Hyrc; Mark P Goldberg
Journal:  Neurobiol Dis       Date:  2013-07-24       Impact factor: 5.996

9.  Neuronal Hemoglobin Expression and Its Relevance to Multiple Sclerosis Neuropathology.

Authors:  Nolan Brown; Kholoud Alkhayer; Robert Clements; Naveen Singhal; Roger Gregory; Sausan Azzam; Shuo Li; Ernest Freeman; Jennifer McDonough
Journal:  J Mol Neurosci       Date:  2016-01-25       Impact factor: 3.444

10.  Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics.

Authors:  Oscar G Vidaurre; Jeffery D Haines; Ilana Katz Sand; Kadidia P Adula; Jimmy L Huynh; Corey A McGraw; Fan Zhang; Merina Varghese; Elias Sotirchos; Pavan Bhargava; Veera Venkata Ratnam Bandaru; Giulio Pasinetti; Weijia Zhang; Matilde Inglese; Peter A Calabresi; Gang Wu; Aaron E Miller; Norman J Haughey; Fred D Lublin; Patrizia Casaccia
Journal:  Brain       Date:  2014-06-03       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.